企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Curocell Inc. was founded in 2016 with the goal of improving the cancer treatment efficacy of CAR-T therapies sold in the global market, and is a cell and gene therapy developer with multiple new drug pipelines, including a CD19 CAR-T therapy that was the first in Korea to receive clinical trial approval for a next-generation CAR-T therapy from the Ministry of Food and Drug Safety, as well as hematologic cancer CAR-T, solid tumor CAR-T, and allogeneic CAR-T therapies. The company is composed of experts in new drug research, development, and production, including basic biology scientists, process development specialists, analytical method development specialists, and clinical development and production technology specialists, and based on this, it has secured platform technology for discovering and developing next-generation CAR-T therapies as well as its own proprietary manufacturing process and analytical technologies.
代表理事
Kim Geonsu
成立日期
2016年12月1日
法人类型
韩国创业板
行业分类
Research and experimental development on medical sciences and pharmacy
法人注册号
13111-0466283
营业执照号
148-88-00557
电话号码
042-863-3698
传真号码
0428633695
公司地址
11 Gukjegwahak 16-ro, Yuseong-gu, Daejeon
产品与服务
评论